期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

乳腺癌芳香化酶抑制剂辅助内分泌治疗：序贯或初始应用争论的结束？——解读BIG1—98临床试验

Aromatase inhibitors in adjuvant endocrine treatment of breast cancer： ending the debate of sequence or upfront？ --interpretation of BIG 1-98 clinical trial
原文传递
导出
摘要 第三代芳香化酶抑制剂（aromatase inhibitors，AI）在绝经后激素受体阳性乳腺癌辅助治疗中占据着重要的地位。与他莫昔芬相比，初始或序贯应用AI均可显著提高乳腺癌患者的预后，但在临床实践中，具体是选择初始还是序贯应用AI一直存在争议。随着BIG1-98临床试验结果的公布及对其数据的解读，可进一步认识并优化AI在乳腺癌临床上的应用。 The third generation of aromatase inhibitors （AI） play an important role in the adjuvant treatment of hormonal positive postmenopausal breast cancer. Compared with tamoxifen, either npfront or sequential using of A! can both significantly improve the outcome of breast cancer patients. However, there is a continuous debate of sequence or upfront usage of AI in clinical applications. With the publication result of BIG 1-98 clinical trial and interpretation of the data, we can further recognize and optimize the usage of AI in breast cancer treatment.
作者 陈小松 沈坤炜
机构地区 上海交通大学医学院附属瑞金医院乳腺疾病诊治中心
出处 《肿瘤研究与临床》 CAS 2010年第3期152-154,共3页 Cancer Research and Clinic
关键词 乳腺肿瘤 芳香化酶抑制剂 肿瘤辅助疗法 Breast neoplasms Aromatase inhibitors Neoadjuvant therapy
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献11

  • 1Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet, 2005, 365:1687-1717.
  • 2The Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopansal women with early breast cancer. N Engl J Med, 2005, 353: 2747-2757.
  • 3Forbes JF, Cuzick J, Buzdar A, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100- month analysis of the ATAC trial. Lancet Oncol, 2008, 9: 45-53.
  • 4Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med, 2004, 350: 1081-1092.
  • 5Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet, 2005, 366: 455-462.
  • 6Mouridsen HT, Giobbie-Hurder A, Mauriac L, et al. BIG 1-98: A randomized double-blind phase Ⅲ study evaluating letrozole and tamoxifen given in sequence as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. 31st Annual San Antonio Breast Cancer Symposium, 2008, Abstract 13.
  • 7BIG 1-98 Collaborative Group, Mouridsen H, Giobbie-Hurder A, Goldhirsch A, et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med, 2009, 361: 766-776.
  • 8Jones SE, Seynaeve C, Hasenburg A, et al. Results of the first planned analysis of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase Ⅲ trial in hormone sensitive postmenopausal early breast cancer. 31st Annual San Antonio Breast Cancer Symposium, 2008, Abstract 15.
  • 9Goss PE, Ingle JN, Martino S, et al. A randomized trim of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med, 2003, 349: 1793-1802.
  • 10Mamounas EP, Jeong JH, Wickerham DL, et al. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 trial. J Clin Oncol, 2008, 26:1965-1971.
肿瘤研究与临床
2010年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部